Advance the development of two antibiotics for use in the pediatric population for the treatment of serious bacterial infections where multidrug-resistant organisms are common, and 2) develop…

Active Definitive Contract Awarded Last action

Contract number
75A50123C00022
Awardee
Awarding agency
Obligated
$47,521,248

Award facts

Contract value 29% obligated
  • $47,521,248.00 Current, with exercised options
  • $164,300,757.00 Potential, with all options
Completion date 30% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
Washington, DC 20001, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00006 · The purpose of this no-cost modification is to extend the period of performance for base period/CLIN0001 through september 30, 2027; update section G.3. Key… $0
Exercise an Option P00005 · The purpose of this modification is to is exercise and fully fund CLIN0002/option 1 $8,550,965
Exercise an Option P00004 · The purpose of this modification is to is exercise and fully fund option 5/CLIN0004, provide supplemental funding for CLIN0001 and CLIN0003, revise the budget… $12,784,824
Supplemental Agreement for work within scope P00003 · No cost extension for clin 0003, update key personnel, add alternate COR, adds/removes clauses based on executive orders $0
Exercise an Option P00002 · Exercise clin 0004 option $4,615,469
Supplemental Agreement for work within scope P00001 $1,047,233
Original award $20,522,757

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive cost-sharing contract to Melinta Therapeutics, LLC on July 6, 2023, with a ceiling value of $164.3 million for the development of two antibiotics for use in the pediatric population to treat serious bacterial infections where multidrug-resistant organisms are common, and for the development of antibiotics for use in public health and biothreat emergencies.

Place of performance is Washington, DC. The contract extends through August 6, 2034. A no-cost modification issued most recently extended the period of performance for the base period through September 30, 2027, updated key personnel in Section G.3, and incorporated FAR and HHSAR deviation updates. No set-aside applies to this award.

Description

As the agency reported it.

Advance the development of two antibiotics for use in the pediatric population for the treatment of serious bacterial infections where multidrug-resistant organisms are common, and 2) develop antibiotics for use in public health and biothreat emergen

Quick answers

Who was awarded contract 75A50123C00022?

75A50123C00022 was awarded to Melinta Therapeutics, LLC by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 6, 2023.

How much is contract 75A50123C00022 worth?

The government has obligated $47,521,248 on 75A50123C00022. Its potential value, with all options, is $164,300,757.

Was contract 75A50123C00022 competed?

The extent of competition for 75A50123C00022 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login